Take-Two Slides Into Correction As Grand Theft Auto Leak Investigation Intensifies

 Take-Two Interactive, whose Rockstar Games studio is developing Grand Theft Auto VI, was hit by a series of leaks last month ahead of the fall release. Bank of America analysts described the leaked footage as "impressive, but unlikely to surprise," while TTWO shares have tumbled into a correction since the leaks surfaced online.

The leaked clips reportedly expose plot details, character scenes, and gameplay mechanics, prompting Rockstar Games to call the leaks "gut-wrenching" and warn that some of the game's surprises may have been spoiled.

According to the Dutch news publication TorrentFreak, TTWO has intensified its search for the person who leaked GTA VI, asking a federal court to seal its latest demand for Discord user data, as the company describes its investigation as "rapidly evolving."

The new filing came Friday, one day after Rockstar Games streamed an extended GTA 6 preview on Netflix and months before the blockbuster title's planned November 19 release.

In mid-August, an account named "Cyberleek" began circulating the leaks. TTWO responded with takedown notices and a series of Digital Millennium Copyright Act subpoenas targeting Discord, Microsoft, X, and YouTube.

Unlike a conventional lawsuit, a DMCA subpoena allows a copyright holder to seek identifying information from an online platform before suing the alleged infringer.

In the new subpoena, filed Friday in the US District Court for the Southern District of New York, TTWO said its "investigation of the infringement at issue is rapidly evolving and ongoing," adding, "Take-Two has identified one additional Discord user and obtained additional identifying information for a previously identified Discord user, as well as additional information concerning the community servers identified in its prior subpoena for which it now seeks more targeted information."

On Monday, the SDNY granted the subpoena request. Last month, Take-Two requested four subpoenas seeking information from Discord, Microsoft, Google, and X as the GTA VI leaks went viral on social media.

TorrentFreak pointed out that TTWO withdrew its YouTube request after facing pushback from a judge.

US technology publication PCMag reported that the leaker, CyberLeek, "has gone silent after posting what appears to be the prologue to GTA 6."

https://www.zerohedge.com/markets/take-two-slides-correction-grand-theft-auto-leak-investigation-intensifies

Rubio told US embassies to press governments on Iran sanctions drive - Axios

 

Secretary of State Marco Rubio instructed US embassies worldwide earlier this week to deliver a formal diplomatic demarche on Operation Economic Outcast to the highest levels of their host governments, Axios reported Wednesday, citing US officials.

White House envoy Steve Witkoff met UAE national security adviser Sheikh Tahnoon bin Zayed Al Nahyan last weekend to discuss next steps on Iran, Axios reported earlier Wednesday.

Treasury Secretary Scott Bessent announced Operation Economic Outcast on Aug. 24, launching a campaign of expanded secondary sanctions aimed at countries and entities that continue doing business with Iran.

Axios also reported that UAE officials had told Washington that any effective pressure campaign would need to include all major countries trading with Iran.

https://www.iranintl.com/en/202609027104

uniQure submits FDA BLA for accelerated approval for Huntington’s gene therapy

 

uniQure submits FDA BLA for accelerated approval and UK MHRA MAA for Huntington’s gene therapy ifezuntirgene inilparvovec (AMT-130)

• William Blair resumed coverage of uniQure with Outperform rating and $73 fair value, citing AMT-130 filings.

https://finviz.com/stock?t=QURE&p=d

Scribe starts Phase 1 trial for cholesterol drug STX-1150

 

Scribe Therapeutics Inc. (NASDAQ: SCTX) reports Q2 2026 results, starts Phase 1 for STX-1150, and outlines post-IPO cash runway

Scribe Therapeutics Inc. (NASDAQ: SCTX) reported second-quarter 2026 financial results and provided pipeline updates, including the start of a first-in-human Phase 1 trial of its LDL-C program STX-1150 in Australia and receipt of more than $25 million in CIRM grants to advance two additional cardiometabolic programs toward clinical entry. The company also detailed its July 2026 IPO and a concurrent private placement to Sanofi, which together generated about $155.5 million in gross proceeds, extending its expected funding runway into the first half of 2029.

Scribe Therapeutics News: Key Takeaways

• Initiated a first-in-human Phase 1 clinical trial in Australia for STX-1150, an in vivo epigenetic silencing therapy targeting PCSK9 for LDL-C lowering; initial clinical data from the single ascending dose portion are expected in the first half of 2027.
• Awarded about $25.7 million in combined non-dilutive grants from the California Institute for Regenerative Medicine: $12.7 million for STX-1200 (Lp(a) lowering) and $13.0 million for STX-1400 (triglyceride lowering), with each program advancing toward clinical entry as early as 2027.
• Completed an upsized IPO and a concurrent private placement to Sanofi, raising approximately $155.5 million in aggregate gross proceeds (before underwriting discounts, commissions, and offering expenses); common stock began trading on Nasdaq on July 24, 2026 under ticker SCTX.
• Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026; the company said this plus approximately $140.6 million of net proceeds from the July 2026 financing provides funding into the first half of 2029.
• Q2 2026 collaboration revenue was $1.9 million (vs. $4.9 million in Q2 2025); net loss was $6.5 million, or $2.62 per share (vs. a net loss of $9.9 million, or $4.08 per share, in Q2 2025).

Scribe Therapeutics Q2 2026: Key Financials

Metric	Q2 2026	Q2 2025	Change
Collaboration revenue	$1.9 million	$4.9 million	-$3.0 million
R&D expense	$8.8 million	$13.9 million	-$5.1 million
G&A expense	$2.5 million	$2.6 million	-$0.1 million
Net loss	($6.5 million)	($9.9 million)	+$3.4 million (lower loss)
Net loss per share (basic and diluted)	($2.62)	($4.08)	+$1.46 (lower loss)
Cash, cash equivalents, and marketable securities	$43.0 million (as of June 30, 2026)	$58.0 million (as of Dec. 31, 2025)	-$15.0 million

The company said it initiated a first-in-human Phase 1 clinical trial of STX-1150 in Australia in mid-2026. The study is intended to evaluate safety, tolerability, and efficacy in adults with elevated LDL-C and increased risk of atherosclerotic cardiovascular disease. STX-1150 is designed as a liver-targeted, in vivo CRISPR-based epigenetic silencing therapy that represses PCSK9 without permanently altering the underlying DNA sequence.

Scribe also highlighted preclinical data it presented at the European Atherosclerosis Society Congress. In non-human primates, the company said a single administration of an STX-1150 ELXR prototype demonstrated PCSK9 silencing of up to 90% and LDL-C reductions of up to 68%, with a 0.75 mg/kg dose producing LDL-C reductions greater than 50% sustained for two years and liver enzyme profiles comparable to saline controls. The company also reported that a toxicology study in non-human primates showed no adverse clinical observations.

Separately, Scribe reported receiving approximately $25.7 million in combined CIRM grants to advance two additional programs toward clinical entry as early as 2027: STX-1200 (targets LPA for Lp(a) lowering using the company's X-Editor technology) and STX-1400 (targets APOC3 for triglyceride lowering using X-Editor). The company cited preclinical study results showing STX-1200 surrogates achieved greater than 95% Lp(a) reduction in non-human primates and STX-1400 surrogates achieved greater than 75% on-target APOC3 editing in non-human primates.

On financing, Scribe said it upsized its initial public offering, priced at $15.00 per share, and completed a concurrent private placement to Sanofi at the IPO price. The company reported approximately $155.5 million in aggregate gross proceeds from the IPO, the full exercise of the underwriters' option, and the private placement (before underwriting discounts, commissions, and offering expenses). As of June 30, 2026, Scribe had $43.0 million in cash, cash equivalents, and marketable securities, and it said the additional approximately $140.6 million in net proceeds from the July 2026 transactions extends its operating runway into the first half of 2029.

Company Commentary

“The second quarter and the weeks immediately following represented a transformational period for Scribe,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics. “We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering. These achievements position us to execute across a broadly differentiated portfolio of CRISPR genetic medicines designed to address the three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built technologies are uniquely poised to democratize access to the cardioprotective effects of beneficial human genetics. Guided by nature's blueprint for improved cardiovascular health, our aim is to shift the treatment paradigm of heart disease from chronic intervention of symptoms toward durable disease prevention and lifespan extension.”

Starting a first-in-human Phase 1 trial moves Scribe's lead program, STX-1150, from preclinical development into the clinic, with an initial readout expected in the first half of 2027. The announcement also indicates additional non-dilutive funding for earlier-stage programs, which could support broader pipeline progress without relying exclusively on equity financing.

From a balance-sheet perspective, the company's July 2026 IPO and concurrent private placement to Sanofi materially increased capital available for operations. Management said the combination of its June 30, 2026 cash balance and the July 2026 net proceeds provides funding into the first half of 2029, which may reduce near-term financing risk as the clinical program advances.

https://stockhouse.com/news/newswire/2026/09/02/scribe-starts-phase-1-trial-for-cholesterol-drug-stx-1150

Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim

 Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.

Guggenheim reiterated a ‘Buy’ rating and a $38 price target on Summit.
The Phase 3 trial compared Ivonescimab plus chemotherapy with AstraZeneca’s Durvalumab plus chemotherapy as an initial treatment.


Ivonescimab showed statistically significant and clinically meaningful improvement in overall survival.Summit Therapeutics (SMMT) remained on investors’ radar on Wednesday after Guggenheim said the positive late-stage biliary tract cancer data from China-based Akeso strengthened confidence in Summit’s upcoming global Phase 3 lung cancer trials.

Guggenheim reiterated a ‘Buy’ rating and a $38 price target

https://stocktwits.com/news-articles/markets/equity/summit-s-global-lung-cancer-trials-gain-credibility-after-akeso-s-phase-3-data-says-guggenheim/cZYVTP7RJYz

Another ActBlue Official Pleads Fifth In House Probe of Alleged Foreign Donations

 by AG News Staff via American Greatness,

Another senior figure at Democratic fundraising platform ActBlue invoked the Fifth Amendment during congressional testimony Tuesday as House Republicans investigate allegations of fraudulent and foreign political donations.

Kimberly Peeler-Allen, a member of ActBlue's board of directors, invoked her constitutional right against self-incrimination while appearing before the House Administration, Judiciary and Oversight committees, according to sources familiar with her testimony.

Kimberly Peeler-Allen, pictured second from the left, attending the 35th Annual Celebrating Women® Breakfast at New York Marriott Marquis Hotel on May 11, 2022, in New York City. Peeler-Allen pleaded the Fifth Amendment on Sept. 1, 2026, during a probe into Democratic fundraising platform ActBlue, for which she is a member of the board of directors. (Monica Schipper/Getty Images for The New York Women's Foundation)

Her decision follows similar moves by other ActBlue officials.

ActBlue co-founder Matt DeBergalis invoked the Fifth during a closed-door deposition Aug. 20, while CEO Regina Wallace-Jones asserted the same right during congressional questioning in June.

The House Administration Committee began investigating ActBlue in 2023 following concerns that the fundraising platform's fraud-prevention procedures were inadequate to prevent illegal foreign donations.

Committee Chairman Bryan Steil, R-Wis., has focused in part on ActBlue's previous practice of not requiring donors to provide credit card CVV security codes.

"We have an entity here with ActBlue, that has raised roughly $20 billion since its creation," Steil told Fox News.

"We want to make sure that they have the fraud prevention protocols in place to make sure that foreign funds are not coming into U.S. elections."

Steil acknowledged that witnesses have a constitutional right to invoke the Fifth Amendment but said their refusal to answer questions has frustrated lawmakers seeking information about ActBlue's operations.

The investigation intensified after The New York Times reported in April that ActBlue's attorneys had warned internally that Wallace-Jones may have provided Congress with a misleading description of the organization's procedures for detecting foreign donations.

Wallace-Jones had described ActBlue's screening system as "multilayered." According to the Times, however, the organization's attorneys warned that ActBlue did not always follow the procedures she described, creating what they characterized as "a substantial risk for ActBlue."

Republicans have denied accusations that the investigation is politically motivated, arguing that foreign money entering American elections would present a serious threat regardless of which party benefits.

ActBlue has denied wrongdoing and has previously said it maintains safeguards against fraudulent and foreign contributions.

https://www.zerohedge.com/political/another-actblue-official-pleads-fifth-house-probe-alleged-foreign-donations

Tax The Rich Foolishness

 The theater kids who have taken over the Democratic Party have brought to the forefront the long-held proposition of the left to tax the rich to pay for a utopian future. Even before the DSA surge, the party insisted there is plenty of money out there, all the government had to do was grab it and problems would be solved. It’s nonsense of course. An even more draconian tax structure than the one we have now wouldn’t fund the federal government for even a year.

Washington, now facing a $40 trillion debt, spent more than $7 trillion in fiscal 2025, doling out an average of almost $21,000 per person. Democrats have always argued that if they could just tax the rich hard enough, they could erase all of society’s ills while eliminating deficits and debt. Either they know better and can’t help but lie, which is an organizational foundation of communism, or their math is below grade-school level.

Using IRS data to make its case, the Cato Institute says that if the federal government in 2023 “had confiscated every dollar earned over half a million dollars, it still would have run a budget deficit.”

If that won’t work, then try harder, right? Go after the villains, the billionaires. So what if Washington seized every asset they owned, not just their annual income, but “every home, property, business, investment, car, and yacht, right down to their kids’ teddy bears — and sold it all for full market value?” asks researcher Jessica Riedl.

Wouldn’t that get the job done? Nope.

“That would raise enough revenue to finance the federal government for nine months,” she says. But not nine months every year. Nine months one time only. “Then, with no billionaires left to pillage, it’s gone — as is your 401(k), because most of that wealth would’ve been liquidated out of the stock market.”

If mugging the billionaires isn’t enough, then we just need more rich people to tax. Let’s hit million-dollar earners with 100% marginal tax rates. That should do it. Not so, says Riedl. It “wouldn’t balance the long-term budget,” even if every one “of those taxpayers would keep working for zero net pay (and they would not).”

Let’s try yet one more time. Let’s tax corporations until they can’t be taxed any more.

Still won’t work, says Riedl.

“The mathematical reality is that there just aren’t enough millionaires, billionaires, and undertaxed corporations to close a 30-year budget deficit of between $115 trillion and $180 trillion.”

The facts won’t stop the Democrats and their socialist progeny taking over the party. They will continue to produce shameless, execrable political grifters such as Bernie Sanders, Elizabeth Warren, Alexandria Ocasio-Cortez, Keith Ellison, Ro Khanna, Zohran Mamdani and the larger assortment of those who blindly vote Democrat.

Their goal? They want no limits on their political power, no boundaries to protect property rights nor the product of everyone else’s labor, no dissent from an agenda that Karl Marx would approve of. They need other people’s money to further their revolution and will go to any means to take it.

https://issuesinsights.com/2026/09/02/tax-the-rich-foolishness/